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Abstract
Background: The HIV epidemic in Russia has been driven by the unsafe injection of drugs, predominantly
heroin and the ephedrine derived psychostimulants. Understanding differences in HIV risk behaviors
among injectors associated with different substances has important implications for prevention programs.
Methods: We examined behaviors associated with HIV risk among 900 IDUs who inject heroin,
psychostimulants, or multiple substances in 2002. Study participants completed screening questionnaires
that provided data on sociodemographics, drug use, place of residence and injection- and sex-related HIV
risk behaviors. HIV testing was performed and prevalence was modeled using general estimating equation
(GEE) analysis. Individuals were clustered by neighborhood and disaggregated into three drug use
categories: Heroin Only Users, Stimulant Only Users, and Mixed Drug Users.
Results: Among Heroin Only Users, younger age, front/backloading of syringes, sharing cotton and
cookers were all significant predictors of HIV infection. In contrast, sharing needles and rinse water were
significant among the Stimulant Only Users. The Mixed Drug Use group was similar to the Heroin Only
Users with age, front/back loading, and sharing cotton significantly associated with HIV infection. These
differences became apparent only when neighborhood of residence was included in models run using GEE.
Conclusion: The type of drug injected was associated with distinct behavioral risks. Risks specific to
Stimulant Only Users appeared related to direct syringe sharing. The risks specific to the other two groups
are common to the process of sharing drugs in preparation to injecting. Across the board, IDUs could
profit from prevention education that emphasizes both access to clean syringes and preparing and
apportioning drug with these clean syringes. However, attention to neighborhood differences might
improve the intervention impact for injectors who favor different drugs.
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Injection drug use is at the heart of Russia's HIV epidemic
and the majority of new infections are associated with
injection drug use [1,2]. Of the approximately 40,000 new
HIV cases registered in Russia in 2003, 76% were among
injection drug users [3]. Heroin and psychostimulants are
the dominant injection drugs of abuse in Russia [1,4]. St.
Petersburg has been one of the most affected cities with
nearly 40,000 reported HIV infections [5,6].
Among St. Petersburg IDUs, the type of drug injected is
associated with incidence and prevalence of HIV infec-
tion. As previously reported, in a sample of drug users
recruited in 2002 and followed for a year, psychostimu-
lant use was associated with HIV incidence [7] while HIV
prevalence was spatially clustered with frequent heroin
use [8]. The behavioral effects of different drug types
could have accounted for these differences. Outside of
Russia, psychostimulant use has been associated with
both HIV risk due to sharing injection equipment and an
increase in HIV cases [9,10]. Historically, psychostimu-
lants used in Russia are 'vint' and 'jeff'. These are home-
made injectable derivatives of ephedrine, pseudoephe-
drine, or phenylpropranolamine (PPA). They cause
amphetamine like effects with release of dopamine and
serotonin and inhibition of dopamine and serotonin
transporters after multiple administrations [11,12]. The
stimulant effects have behavioral consequences including
impulsivity, increased sexual activity, and injection risk
taking including bingeing.
The high prevalence of stimulant use has been a signifi-
cant concern in the fight against HIV. There are an esti-
mated 35 million amphetamine type stimulant users
worldwide [13,14], the second most widely used illicit
drug after cannabis (161 million users). Opiates (16 mil-
lion users including 11 million heroin users) remain the
leading problem drug as measured by treatment demand.
Opiate users constitute the majority of IDUs and under-
standing which behaviors put them at risk for HIV is a cru-
cial component in fighting new infections. The situation
in Russia is similar to patterns seen worldwide [1,15].
The goal of the present study was to compare high risk
injecting practices between injection heroin users, stimu-
lant users, and mixed drug users. A cohort of IDUs was
recruited into the NIH, HIV Prevention Trials Network
(HPTN) 033 HIV Prevention Preparedness Study, a mult-
icentre study whose primary objective was to estimate
rates of HIV seroincidence among persons who could par-
ticipate in future HIV prevention studies. The incidence
rate was 4.5/100 person years [7] with stimulant use being
the strongest correlate to HIV acquisition. Secondarily, the
study sought to describe the characteristics and risk behav-
iors of the screened cohort. HIV prevalence among this
study cohort was 30% placing it among the worst epidem-
ics among IDUs in Europe [16].
Gathering information on HIV infection and risk behav-
iors is necessary to focus interventions appropriately. The
ultimate goal in studying this vulnerable population is to
gain practical information that can be used to reduce HIV
transmission by means of public health interventions;
toward this end, we identified risks typical to different
substance use patterns, information which can inform
prevention efforts.
Methods
Participant Recruitment
Active IDUs were recruited over a 10 month period by
peer recruitment, street outreach and from rehabilitation
and detoxification facilities. Details of the recruitment
patterns [16] and spatial distribution of participants' place
of residence that have been reported previously [8] dem-
onstrated that the sample was broadly distributed
throughout the city of St. Petersburg, to some extent over-
coming limitations imposed in a non-random sampling if
only a single recruitment method had been employed.
Individuals were eligible if they injected drugs at least
three times per week in the previous month or if on at
least three occasions in the previous three months they
used injection equipment after another person. Active
injection was assessed through detection of recent injec-
tion stigmata. Individuals with apparent psychiatric disor-
ders were excluded. Initially, individuals 18 years or older
were recruited but this was expanded to include those 16
years or older near the end of the recruitment period.
Institutional Review Boards (IRBs) at The Biomedical
Center and the University of North Carolina approved the
study before it started as well as the change in protocol
that lowered the age of consent. Additionally, a commu-
nity advisory board was developed in St. Petersburg for
the purpose of ensuring that participants' rights were pro-
tected. Screening was conducted as part of the HIV Preven-
tion Trials Network (HPTN) 033 study designed to enroll
a cohort of seronegative IDUs for a year's follow-up study
preparatory to initiating prevention in St. Petersburg Rus-
sia.
The sample accrued for this report consisted of all
screened individuals, regardless of HIV serostatus. The
time of seroconversion for all HIV positive individuals
could not be determined, so the sample must be consid-
ered a mix of seronegative and seroprevalent individuals.
Data Collection
After giving informed consent, individuals completed
baseline questionnaires that collected data on sociodemo-
graphics, drug use, place of residence and injection- and
sex-related HIV risk behaviors and were tested for HIVPage 2 of 7
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covered the three months prior to the interview whereas
questions of sexual activity covered the six months prior
to the interview. The data collection instrument was com-
mon to all four international sites participating in HPTN
033.
Statistical Methods
In a previous analysis, taking into account the spatial dis-
tribution of study participants across the city, we were able
to locate exact addresses for 788 of the 900 participants
screened and we explored the co-clustering of HIV preva-
lence and variables from the questionnaire using the
Moran's I statistic and the Nearest Neighbor algorithm
[8]. In the current analysis, we sought to overcome the
loss of statistical power from the elimination of 112
observations in the spatial analysis while adjusting for the
statistically significant clustering. Therefore, we applied
generalized estimating equations (GEE) using the partici-
pant's neighborhood of residence as a clustering factor to
capture the effects of the previously observed spatial cor-
relation. For this analysis, individual point data were
aggregated by residential districts using ESRI ArcMap GIS
software with the "HawthTools" extension. One subject
could be included in this analysis for a total of sample of
899. Participants identified sixteen discrete neighbor-
hoods in which they resided; the thirteen within the city
boundaries are included in the maps.
The sixteen neighborhood grouping proved to be consist-
ent with the results of the purely spatial analysis in that
risk clusters generated ellipsoids that generally followed
residential neighborhoods, making this a rational aggre-
gating factor for GEE analysis. Given the dichotomous
nature of the dependent variable, HIV prevalence, we
applied logistic regression within GEE as suggested by
Shaw et al. [17].
Three software programs were necessary to achieve a
robust statistical analysis, due to the spatial structure of
the data and the differing capabilities of each program. It
should be noted that the statistical models presented in
this paper were consistent across all three software pro-
grams we applied, with the variables listed as significant
or not significant remaining so, despite small variations in
standard errors. However, to maximize the robustness of
the analysis, we felt compelled to select different software
for different applications as follows. An initial run of pre-
liminary statistical models on Splus 7.0 and the xtgee
command in STATA 9.2 suggested that accounting for
clustering by neighborhood under a GEE would unmask
additional relationships between HIV and demographic
and behavioral variables. Our variable reduction strategy
tested for univariate associations individually by logistic
regression within GEE as suggested by Shaw et al [17]. In
contrast to Shaw et al, we applied a stricter criterion of P <
0.10 for the resultant Wald statistic, versus P < 0.20 for
candidate variables. Candidate variables were then
entered into a multivariate model again using the logistic
regression within the GEE framework of the STATA xtgee
command. Variables not significant at the P < 0.05 were
eliminated with the exception of an education level varia-
ble and a housing variable, since they did not seem rele-
vant to possible harm reduction strategies.
Shaw et al. also note that parameter estimation in GEE is
through quasi-likelihood [17]; therefore, standard model
selection criteria such as stepwise techniques and the
Akaiki Information Criteria (AIC), which are based on
likelihood methods, were not appropriate. We therefore
applied the Quasi-likelihood Information Criteria (QIC)
as proposed by Pan calculated in a module developed for
STATA software by Cui for variable reduction and model
selection [18,19]. Since data were collected from only six-
teen neighborhoods in St. Petersburg – less than the thirty
clusters that are usually required for GEE – we accounted
for the low number by using a "jackknife" standard error
as recommended by Hardin and Hibble (2003). "Jack-
knife" standard errors are not available in Splus, so the
analysis was re-run using the GEE algorithm in the R geep-
ack software package add-on developed by Yan and col-
leagues [20,21]. Significance levels in this algorithm are
based on the Wald statistic.
Finally, we disaggregated the data by current drugs
injected creating three distinct categories of drug user
based on the drug(s) injected in past 30 days: heroin only
users, stimulant only users, and mixed drug users.
Results
We included data from a total of 899 recruited individu-
als. As previously reported, the sample was 71% male with
a median age of 24, four in five had completed secondary
education and half had some post-secondary education,
43% of the sample was unemployed at the time of inter-
view, only 17% was living in a residence that they owned
or rented; and 30% was confirmed HIV seropositive [16].
As noted in Table 1, 430 (48%) reported heroin use only,
30 (3%) stimulant use only, and 439 (49%) mixed drug
use. All those in the mixed drug use category injected had
injected both heroin and psychostimulants in the three
Table 1: HPTN Drug Use Distribution
Drug Use Count % of Total
Heroin Only 430 47.8
Stimulants Only 30 3.3
Mixed 439 48.8
Total 899Page 3 of 7
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mixed drug use category) reported injecting other drugs.
The three groups did not differ in their demographic char-
acteristics.
Spatial analysis at the district level found levels of HIV
prevalence that ranged from 20% to 60% (mean = 31.9%
± 12.6%, median 26.1%) with minor positive skewness
(Figure 1A). Spatial analysis also revealed that stimulant
only users resided in only seven of the city's thirteen dis-
tricts, but they did not appear to be concentrated in spatial
contiguous districts (Figure 1B).
For the sample as a whole, the choice of drug injected did
not predict differences in injection frequency, behaviors,
or practices. Conversely, neighborhood alone in the
absence of the inclusion of the type of drug used did not
reveal significant associations between HIV prevalence
and risk behaviors. However, when we adjusted for loca-
tion of residence using GEE and looked specifically at the
behavioral attributes associated with HIV infection we
could detect significant differences among users of differ-
ent drugs (Table 2). The GEE models of HIV prevalence
among heroin only users revealed that younger age, front-
or back-loading, sharing cotton, and sharing cookers were
significant. The same variables, with the exception of shar-
ing cookers, were significant among the mixed drug users.
The stimulant only users were different from the other
injectors in two injection risk categories. Those who were
HIV positive within the group were more likely to engage
in receptive needle sharing but were less likely to share
rinse water.
Discussion
These data revealed that drug users in St. Petersburg who
inject only stimulants and live in certain neighborhoods
Spatial Distribution of HIV Cases and Injection Drugs within the City of St. PetersburgFigure 1
Spatial Distribution of HIV Cases and Injection Drugs within the City of St. Petersburg. Data from 899 participat-
ing injection drug users screened at baseline were sorted by district of residence. For each district, the number of participants, 
the HIV prevalence, and the percentage of injectors who injected only heroin, only amphetamine-type psychostimulants (ATS), 
or both within the 30 days prior to entering the study are included on the embedded table. The maps display HIV prevalence 
(A) and type of drug injected (B) with the size of the pie charts proportional to the number of participants who resided in each 
of the 13 neighborhoods within the city limits of St. Petersburg. For HIV prevalence, the dark part of the pies represents the 
seropositive cases. For drug injected, the open part of the pies represents heroin only injectors, the dark part represents ATS 
only injectors, and the striped part represents injectors of both kinds of drug.
City District 1 2 3 4 5 6 7 8 9 10 11 12 13
# Participants 40 84 74 189 34 116 20 23 39 37 15 63 121
% HIV seropositive 22.5 25.0 25.7 39.2 26.5 20.0 20.0 26.1 46.2 48.6 60.0 23.8 30.6
Drug Injected
% heroin only 52.5 55.0 51.4 41.0 38.2 43.1 50.0 39.1 56.4 51.4 41.2 50.8 55.4
% heroin and ATS 42.5 35.5 48.6 55.8 61.8 50.0 50.0 60.9 43.6 48.6 51.2 43.6 43.8
% ATS only 5.0 9.5 0.0 3.2 0.0 6.9 0.0 0.0 0.0 0.0 7.6 5.6 0.8 
A BPage 4 of 7
(page number not for citation purposes)
Harm Reduction Journal 2009, 6:22 http://www.harmreductionjournal.com/content/6/1/22appear to constitute a unique population in terms of HIV
exposure risk, even though their proportion in the sample
is small. Almost all (97%) drug users in the cohort
injected heroin (either alone or in combination with or in
addition to stimulants) while only a small number
injected stimulants only. Stimulant users did not differ
demographically from the heroin users as a whole, but the
risk behaviors associated with HIV infection did when
considered in the context of neighborhood of residence.
Whereas front or back-loading and sharing non-syringe
equipment were significantly associated with HIV infec-
tion among heroin users (either those who injected only
heroin or both heroin and stimulants), receptive syringe
sharing was significant among the stimulant only users.
Studies conducted both in the former Soviet Union and
elsewhere in the world have reported differences in risk
behavior between stimulant injectors and opioid injec-
tions [22-24]. A study of risk behaviors by type of drug
used in Ukraine found front and back-loading was more
common among opiate injectors while reusing a syringe
was more common among stimulant users [25]. While
heroin has been associated with passivity, regular injec-
tion and decreased sexual activity, stimulant use has been
associated with aggression, frequent, binge injection, nee-
dle sharing, increased sexual activity and young age [26].
It has been suggested that contrasting physiologic
responses to opiates versus stimulant drugs result in dif-
ferent risk profiles for HIV [11,27-29]. For St. Petersburg,
this is supported by the observation that frequent stimu-
lant use is the primary factor associated with seroconver-
sion [7]. The present analysis reveals that even though
stimulant users share demographic and behavioral char-
acteristics with heroin users, their behavior distinguishes
them in terms of HIV risk as ascertained by prevalence
rates.
Our data are subject to limitations. First, the number of
injectors who used only stimulants was quite small. Given
that injection of stimulants only is unusual among drug
users in Russia as a rule, increasing the sample size is
unlikely to yield many additional such individuals
[1,15,30]. Second, associations between risk and preva-
lent HIV infection were revealed only when correlation by
residence was included in the analysis, which suggests that
geographic differences in risk may be as important as dif-
ferences in the type of drug injected. Further research will
be needed to determine if the choice of drug remains a sig-
nificant factor in predicting transmission of HIV among
drug injectors in St. Petersburg. Third, while our sample
appears to be representative of drug users in St. Petersburg
and is distributed randomly across the city [8], the results
may not be generalizable to populations outside of St.
Petersburg. However, if characteristic effects and prepara-
tion processes for the different drugs explain some of our
observed behavioral differences then the differences could
occur among drug users in other settings. Fourth, our data
analysis permitted us to identify associations that link
prevalent, but not incident cases of HIV to drug type,
injection risks, and geography. It must be noted however,
that when we followed 520 seronegative individuals in
our sample for an additional year, we found that psycho-
stimulant use was strongly associated with incident infec-
tions, with hazard ratios of 8.1 for individuals who made
three or more psychostimulant injections weekly versus
those who made none [7] and 5.5 for psychostimulant
only injectors versus heroin only injectors. However, no
injection practices were associated with incidence, a con-
sequence of the low power provided by the smaller
number of psychostimulant injectors in the seronegative
cohort. These findings lead to the hypothesis that there is
an association between receptive syringe sharing, which
was more common among the psychostimulant only
injectors, and HIV transmission, but more research would
be needed to test this hypothesis. Finally, needle and
syringe sharing is a widely recognized risk factor for
parenteral infections and may be more socially unaccept-
able than sharing other drug preparation equipment. This
could result in a socially desirable response bias leading to
under-reporting of needle and syringe sharing compared
with other equipment sharing behaviors. However, this
under-reporting would not account for the association of
stimulant injection, receptive syringe sharing, and HIV
prevalence in one small subset of the population while
failing to find such an association in a larger subset given
the statistical power of the larger subset.
Table 2: GEE Wald Statistic P values of Unsafe Injection Behaviors Related to HIV Prevalence by Drug Use
Variable Heroin Only Mixed Drug Stimulant Only
Younger Age 0.012 <0.001 0.784
Share with front- or back-loading 0.007 <0.001 0.754
Receptive syringe sharing 0.252 0.082 0.017
Sharing cotton 0.045 <0.001 0.092
Sharing cooker 0.014 0.098 0.456
Sharing rinse water 0.188 0.118 =0.001
*P values in bold are significant; italics are negative relationshipsPage 5 of 7
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exact impact was hard to determine. Since psychostimu-
lant only injection was associated with certain city dis-
tricts, with receptive syringe sharing, and with subsequent
seroincidence [7], it seems likely that the interaction of a
risky injection practice with districts in which HIV preva-
lent cases were already clustered [8] is sufficient to explain
the increased likelihood of HIV transmission among psy-
chostimulant injectors. The one district with both inci-
dent infections and psychostimulant injection was (and
remains) a fairly typical residential district of apartment
blocks connected to the rest of the city by bus, metro, and
rail. Since little neighborhood ethnography has been con-
ducted to study local variations in the drug scene across
districts in St. Petersburg, it is hard to speculate on neigh-
borhood contextual factors that might have further
enhanced risk for injectors who resided there.
In conclusion, differences in drug preparation and distri-
bution practices for opioid versus stimulant injection may
account for some differences in risk and exposure to HIV
and other bloodborne viruses [4,31]. Some of these differ-
ences may be reflected in the spatial component of our
findings – that neighborhood of residence is an important
covariate when studying the relationship between HIV
prevalence and risk behaviors. In designing targeted inter-
ventions, it becomes important to address both the drug
type and the neighborhood differences since they result in
distinct routes of infection. More generally, intervention
programs to reduce HIV among this population should
identify and focus on risk behaviors specific to the type of
drug used and the social context in which is it used [32].
Across the board, IDUs could profit from prevention edu-
cation that emphasizes both access to clean syringes and
preparing and apportioning drug with these clean
syringes, but slight differences in emphasis and attention
to neighborhood differences might improve the interven-
tion impact for injectors who favor different drugs.
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